Evogene Ltd. (EVGN) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.30
↓-97% vs avg
5yr avg: 8.74
30Y Low0.7·High31.1
ROE
↓
-75.8%
↑-30% vs avg
5yr avg: -58.3%
30Y Low-76%·High-5%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EVGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Evogene Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7M | $11M | $38M | $29M | $673M | $1.7B | $391M | $510M | $790M | $1.3B | $2.0B |
| Enterprise Value | $4M | $8M | $29M | $12M | $643M | $1.7B | $360M | $504M | $786M | $1.3B | $2.0B |
| P/E Ratio → | -0.27 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.80 | 1.25 | 6.80 | 17.22 | 723.25 | 1651.98 | 519.87 | 291.88 | 233.60 | 198.42 | 183.10 |
| P/B Ratio | 0.30 | 0.72 | 1.34 | 0.83 | 10.61 | 30.20 | 6.50 | 10.14 | 11.38 | 14.87 | 19.64 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EVGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.97 | 5.16 | 7.04 | 691.36 | 1609.88 | 477.67 | 288.56 | 232.58 | 197.92 | 182.18 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
EVGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Evogene Ltd. earns an operating margin of -255.4%. Operating margins have expanded from -1774.0% to -255.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -75.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.8% | 39.8% | 24.8% | -105.9% | -222.7% | -217.4% | -312.1% | -89.5% | -38.5% | -11.9% | 12.6% |
| Operating Margin | -255.4% | -255.4% | -467.9% | -1774.0% | -3386.0% | -2580.3% | -3019.9% | -1216.6% | -644.3% | -322.5% | -161.0% |
| Net Profit Margin | -193.7% | -193.7% | -423.4% | -1590.3% | -2988.5% | -2247.5% | -2405.3% | -1188.2% | -616.3% | -299.6% | -154.7% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -75.8% | -75.8% | -75.2% | -54.2% | -46.2% | -39.9% | -32.8% | -34.7% | -26.6% | -20.5% | -15.7% |
| ROA | -36.2% | -36.2% | -44.5% | -40.2% | -37.5% | -32.6% | -27.9% | -30.5% | -24.0% | -18.8% | -14.3% |
| ROIC | -102.4% | -102.4% | -106.5% | -86.5% | -100.8% | -96.9% | -46.8% | -28.9% | -21.8% | -17.8% | -13.2% |
| ROCE | -66.5% | -66.5% | -55.8% | -49.6% | -47.8% | -42.0% | -38.3% | -33.7% | -26.6% | -21.3% | -15.8% |
EVGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $15M exceeds total debt of $13M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.87 | 0.87 | 0.40 | 0.34 | 0.04 | 0.04 | 0.05 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.16 | -0.32 | -0.49 | -0.47 | -0.77 | -0.53 | -0.12 | -0.05 | -0.04 | -0.10 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -175.27 | -175.27 | -154.33 | -123.30 | -78.14 | -99.76 | -64.24 | -150.74 | -168.88 | -136.06 | -91.90 |
Net cash position: cash ($15M) exceeds total debt ($13M)
EVGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.15x means Evogene Ltd. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 6.71x to 1.15x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.15 | 1.15 | 4.96 | 6.71 | 8.27 | 5.36 | 8.53 | 10.22 | 15.61 | 17.13 | 18.51 |
| Quick Ratio | 1.06 | 1.06 | 4.95 | 6.61 | 8.25 | 5.36 | 8.53 | 10.22 | 15.61 | 17.13 | 18.51 |
| Cash Ratio | 0.82 | 0.82 | 4.47 | 6.29 | 7.83 | 4.98 | 8.16 | 10.03 | 15.38 | 16.86 | 17.85 |
| Asset Turnover | — | 0.21 | 0.11 | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | 0.04 | 0.07 | 0.10 |
| Inventory Turnover | 2.82 | 2.82 | 55.80 | 6.09 | 32.62 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 63.77 | 52.03 | 174.98 | 460.76 | 760.88 | 586.52 | 155.86 | 87.77 | 65.58 | 115.31 |
EVGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Evogene Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $5M | $4M | $41M | $37M | $26M | $26M | $26M | $25M | $25M |
Peer Comparison
Compare EVGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EVGNYou | $7M | -0.3 | — | — | 39.8% | -255.4% | -75.8% | -102.4% | — |
 PGEN | $1B | -8.8 | — | — | -8.7% | -3440.2% | -160.8% | -152.8% | — |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 CTVA | $53B | 49.4 | 13.4 | 18.9 | 43.6% | 15.1% | 4.5% | 8.5% | 0.7 |
 FMC | $2B | -0.8 | — | — | 37.0% | -54.4% | -67.8% | -21.2% | — |
 AMGN | $178B | 23.1 | 14.1 | 21.9 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 BIIB | $28B | 21.7 | 11.4 | 13.8 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 ICL | $8B | 33.3 | 7.7 | 59.6 | 30.6% | 9.8% | 3.7% | 6.3% | 2.1 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See EVGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVGN vs PGEN
Side-by-side business, growth, and profitability comparison vs Precigen, Inc..
Start ComparisonEVGN — Frequently Asked Questions
Quick answers to the most common questions about buying EVGN stock.
What is Evogene Ltd.'s P/E ratio?
Evogene Ltd.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
What is Evogene Ltd.'s ROE?
Evogene Ltd.'s return on equity (ROE) is -75.8%. The historical average is -34.6%.
Is EVGN stock overvalued?
Based on historical data, Evogene Ltd. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Evogene Ltd.'s profit margins?
Evogene Ltd. has 39.8% gross margin and -255.4% operating margin.